Our people invest in cutting edge biotechnology research. Our strategy allows us to place investments into companies from start up to commercialization. We focus on scalability and differentiation which can potentially bring radical benefits to patients and life changing treatments.
Our investment strategy is focused on the specific areas of pain, depression and mental illness. By investing in pioneering techniques such as micro-dosing using organic compounds and synthetic molecules, we are focussing on ground breaking research with the aim of providing superior wellness benefits with less side effects, better for people and the planet.
We understand that addressing perceptions and being part of the education process into these new substances and their application is essential in bringing the products from idea to development to market. The requirement for credible research, peer reviewed studies, trials and patenting running along with legislative and government approval is an area we specialize in.
Over 100 years of experience in business, consulting, capital markets, corporate finance, and healthcare services.
We help accelerate business plans and achieve revenues; driving significant growth to investors as well as our shareholders.
We partner with first mover, high growth companies, and provide them with access to capital, resources, and infrastructure.
We take an active role in building brand recognition from inception through to execution.
Vancouver April 15, 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (“Xtacy Therapeutics” or the “Company”) is pleased to announce that today it...
Read More
Vancouver, February, 13, 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (the “Company”) is providing a bi-weekly default status update in accordance...
Read More
Vancouver, February 7th 2024 – XTACY THERAPEUTICS CORP. (CSE: XTCY) (Frankfurt: O3X4) (OTCQB: XTCYF) (“Xtacy” or the “Company”) is pleased to announce an LOI with...
Read More
